Hematology-focused VC fund expects deal flow from inside, outside NYBC
$50M fund launched by New York Blood Center has already begun investing, typically as a syndicate partner
A new fund launched by the New York Blood Center is aiming to be a syndicate partner for VCs investing in innovative blood products, including therapeutics developers and cell therapy manufacturers.
The center has provided an initial $50 million commitment to NYBC Ventures, which it believes is the first fund of its kind. The fund has made a handful of investments thus far; it hopes to funnel returns back into new investments, becoming an evergreen fund...